• 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br Corfield J Perera M Bolton


    15. Corfield J, Perera M, Bolton D, Lawrentschuk N. 68 Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World J Urol. 2018;36:519–27.
    16. Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM. [68 Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39:1085–6. 
    18. Steiner C, Vees H, Zaidi H, Wissmeyer M, Berrebi O, Kossovsky MP, et al. Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence. Nuklearmedizin. 2008:48.
    19. Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, Vöö S, et al. Extent of dis-ease in recurrent prostate cancer determined by [68 Ga]PSMA-HBED-CC PET/CT in relation to PSA levels PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging. 2016;43:397–403.
    20. Medina-Ornelas SS, García-Pérez FO, Hernández-Pedro NY, Arellano-Zarate AE, Abúndiz-López BL. Correlación entre el volumen molecular tumoral evaluado con PET/TC con 68 Ga-PSMA y los niveles de antígeno prostático específico. Rev Esp Med Nucl Imagen Mol. 2018;37:223–8.
    21. Soydal C, Urun Y, Suer E, Nak D, Ozkan E, Kucuk ON. PSA levels as a predictor of 68 Ga PSMA PET/CT positivity in patients with prostate cancer? Q J Nucl Med Mol Imaging. 2018.
    22. Wei J, Zhu H, Liao X. Trigger pSA predicting recurrence from positive choline PET/CT with prostate cancer after initial treatment. Oncotarget. 2018;9:14630–41.
    23. Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-fluoromethylcholine versus 68 Ga-PSMA PET/CT in prostate cancer patients who Thymoquinone have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56: 1185–90.
    24. Chiaravalloti A, di Biagio D, Tavolozza M, Calabria F, Schillaci O. PET/CT with 18F-choline after radical prostatectomy in patients with PSA ≤ 2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection? Eur J Nucl Med Mol Imaging. 2016;43:1418–24.
    25. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the 68 Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209.
    26. Rahbar K, Boegemann M, Yordanova A, Eveslage M, Schäfers M, Essler M, et al. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A ret-rospective analysis of overall survival. Eur J Nucl Med Mol Imaging. 2018;45: 12–9.
    Contents lists available at ScienceDirect
    journal homepage:
    Assessment of human pancreas cancer tissue and precursor lesions via a fluorophore with inherent PDAC selectivity
    Ian R. Munhenzvaa, Connor W. Barthb, Martha Sibrian-Vazqueza, Lei G. Wangb, Jorge O. Escobedoa, Summer L. Gibbsb,c,d, Robert M. Strongina,d,
    a Department of Chemistry, Portland State University, 1719 SW 10th Avenue, Portland, OR 97201, United States
    b Biomedical Engineering Department, Oregon Health & Science University, 3303 SW Bond Avenue, Portland, OR 97239, United States
    c Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, United States
    d OHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University, 2730 SW Moody Avenue, Portland, OR 97201, United States
    Pancreatic cancer
    Tumor targeting
    Fluorescence imaging
    Frozen section 
    The current five-year survival rate of < 5% for pancreatic ductal adenocarcinoma (PDAC) is compounded by late diagnosis, a lack of PDAC-specific intraoperative guidance to ensure complete resection, and the ineffectiveness of current therapies. Previously, utilizing compound 1, a fluorophore with inherent PDAC selectivity, PDAC was visualized both in vivo and ex vivo in a murine model. In the current study, human PDAC tissue is targeted. Compound 1 selectively stains ducts of the adenocarcinoma versus the surrounding stroma, enabling the imaging of PDAC in frozen tissue sections with high contrast. To enhance the potential of 1 for intraoperative applica-tions, the ex vivo staining protocol was optimized for rapid margin assessment, with a final staining time of ~15 min. To measure diagnostic performance, the area under a receiver operating characteristic (ROC) curve was measured for the identification of ductal adenocarcinoma vs. stroma. The bright fluorescence contrast en-abled quantitative determination of PDAC (or precancerous PanIN lesions) versus healthy pancreas tissue in human tissue array samples.